BRPI0915383A2 - composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica. - Google Patents

composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica.

Info

Publication number
BRPI0915383A2
BRPI0915383A2 BRPI0915383A BRPI0915383A BRPI0915383A2 BR PI0915383 A2 BRPI0915383 A2 BR PI0915383A2 BR PI0915383 A BRPI0915383 A BR PI0915383A BR PI0915383 A BRPI0915383 A BR PI0915383A BR PI0915383 A2 BRPI0915383 A2 BR PI0915383A2
Authority
BR
Brazil
Prior art keywords
treating
individual suffering
neurodegenerative
compound
methods
Prior art date
Application number
BRPI0915383A
Other languages
English (en)
Inventor
Andreas RITZÈN
Jacob Nielsen
Jan Kehler
John Paul Kilburn
Mohamed M Farah
Morten Langgard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI0915383A2 publication Critical patent/BRPI0915383A2/pt
Publication of BRPI0915383B1 publication Critical patent/BRPI0915383B1/pt
Publication of BRPI0915383B8 publication Critical patent/BRPI0915383B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915383A 2008-06-20 2009-06-19 composto derivado de fenilimidazol e sua composição farmacêutica. BRPI0915383B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200800855 2008-06-20
DKPA200800855 2008-06-20
DKPA200900402 2009-03-24
DKPA200900402 2009-03-24
DKPA200900519 2009-04-22
DKPA200900519 2009-04-22
PCT/DK2009/050134 WO2009152825A1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors

Publications (3)

Publication Number Publication Date
BRPI0915383A2 true BRPI0915383A2 (pt) 2015-11-03
BRPI0915383B1 BRPI0915383B1 (pt) 2020-09-15
BRPI0915383B8 BRPI0915383B8 (pt) 2021-05-25

Family

ID=40902594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915383A BRPI0915383B8 (pt) 2008-06-20 2009-06-19 composto derivado de fenilimidazol e sua composição farmacêutica.

Country Status (28)

Country Link
US (1) US8841297B2 (pt)
EP (1) EP2318394B1 (pt)
JP (1) JP5930714B2 (pt)
KR (3) KR101703938B1 (pt)
CN (2) CN102124002B (pt)
AR (1) AR072199A1 (pt)
AU (1) AU2009259209B2 (pt)
BR (1) BRPI0915383B8 (pt)
CA (1) CA2728335C (pt)
CL (2) CL2010001467A1 (pt)
CO (1) CO6321263A2 (pt)
CY (1) CY1115001T1 (pt)
DK (1) DK2318394T3 (pt)
EA (2) EA018880B1 (pt)
ES (1) ES2456349T3 (pt)
HK (1) HK1159632A1 (pt)
HR (1) HRP20140232T1 (pt)
IL (1) IL209834A (pt)
MX (1) MX2010014136A (pt)
MY (1) MY152949A (pt)
NZ (1) NZ589926A (pt)
PL (1) PL2318394T3 (pt)
PT (1) PT2318394E (pt)
RS (2) RS53226B (pt)
SI (1) SI2318394T1 (pt)
TW (1) TWI501965B (pt)
WO (1) WO2009152825A1 (pt)
ZA (1) ZA201100109B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
JP5911476B2 (ja) 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JP5785548B2 (ja) 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
US9029536B2 (en) * 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP5820887B2 (ja) * 2010-11-10 2015-11-24 ハー・ルンドベック・アクチエゼルスカベット 放射性標識されたフェニルイミダゾールベースのリガンド
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
US8349824B2 (en) * 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
US9540379B2 (en) * 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
AU2012219316A1 (en) 2011-02-18 2013-10-03 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2013005798A1 (ja) * 2011-07-06 2013-01-10 持田製薬株式会社 新規含窒素複素環誘導体
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) * 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013178572A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
IN2015DN00345A (pt) 2012-06-19 2015-06-12 Sunovion Pharmaceuticals Inc
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
EP2963037B1 (en) * 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
NZ725161A (en) 2014-04-23 2017-10-27 Dart Neuroscience (Cayman) Ltd Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
US20200140446A1 (en) 2018-11-06 2020-05-07 H. Lundbeck A/S 5,8-dimethyl-2-[2-(1-methyl-4-phenyl-1h-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate
WO2020094592A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments
CN110981813A (zh) * 2019-12-19 2020-04-10 西安近代化学研究所 一种2-氰基-5-芳基-1h-咪唑类化合物的合成方法
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036840A (en) 1972-06-07 1977-07-19 Icn Pharmaceuticals 2-Substituted-s-triazolo[1,5a]pyrimidines
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
MXPA05013553A (es) * 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.
CA2556413A1 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
BRPI0508556A (pt) 2004-03-08 2007-08-07 Wyeth Corp moduladores de canal iÈnico
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
JP2009527560A (ja) * 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a

Also Published As

Publication number Publication date
KR20170134781A (ko) 2017-12-06
CL2010001467A1 (es) 2011-08-05
DK2318394T3 (en) 2014-03-24
CN102124002A (zh) 2011-07-13
KR101703938B1 (ko) 2017-02-07
EA018880B1 (ru) 2013-11-29
SI2318394T1 (sl) 2014-07-31
CO6321263A2 (es) 2011-09-20
KR102025487B1 (ko) 2019-09-25
CA2728335C (en) 2016-05-24
MX2010014136A (es) 2011-01-21
RS53704B1 (en) 2015-04-30
KR20170016523A (ko) 2017-02-13
MY152949A (en) 2014-12-15
CA2728335A1 (en) 2009-12-23
CN102482262B (zh) 2014-06-25
TWI501965B (zh) 2015-10-01
EP2318394A1 (en) 2011-05-11
WO2009152825A1 (en) 2009-12-23
EA201170061A1 (ru) 2011-08-30
EA021410B1 (ru) 2015-06-30
NZ589926A (en) 2011-09-30
ZA201100109B (en) 2012-03-28
AU2009259209B2 (en) 2013-08-01
CN102482262A (zh) 2012-05-30
AR072199A1 (es) 2010-08-11
US20120190685A1 (en) 2012-07-26
HK1159632A1 (en) 2012-08-03
CN102124002B (zh) 2014-06-25
EP2318394B1 (en) 2014-01-22
JP5930714B2 (ja) 2016-06-08
PL2318394T3 (pl) 2014-09-30
KR20110020845A (ko) 2011-03-03
HRP20140232T1 (hr) 2014-04-11
CY1115001T1 (el) 2016-12-14
TW201000481A (en) 2010-01-01
IL209834A0 (en) 2011-02-28
CL2011003205A1 (es) 2012-06-22
EA201270046A1 (ru) 2012-05-30
AU2009259209A1 (en) 2009-12-23
PT2318394E (pt) 2014-04-03
US8841297B2 (en) 2014-09-23
RS53226B (en) 2014-08-29
BRPI0915383B1 (pt) 2020-09-15
ES2456349T3 (es) 2014-04-22
BRPI0915383B8 (pt) 2021-05-25
JP2011524381A (ja) 2011-09-01
IL209834A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
BRPI0915383A2 (pt) composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica.
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0619586A2 (pt) método para o tratamento ou prevenção de um distúrbio associado com cd40
BRPI1012023A2 (pt) método implementado por computador, e métodos para operar um sistema de reservatório e para avaliar um esquema de injeção padrão ou um esquema de injeção periférica.
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0823030A2 (pt) Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0916576A2 (pt) pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0817664A2 (pt) Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
BRPI0610514A2 (pt) composto, composição farmacêutica, e, método de tratamento de um distúrbio
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0819117A2 (pt) sistema de dispensação de composição de combustível, e, método para fornecer uma composição de combustível
BRPI0815091A2 (pt) Método e sistema para determinar a autenticidade de um produto farmacêutico.
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1008869A2 (pt) nanopartícula, composto, composição farmacêutica, método para tratar câncer ou metástase, e, método de liberação prolongada de um composto de platina
BRPI0920141A2 (pt) sistema e método para tratar uma formação de subsuperfície.
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0912111A2 (pt) composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BRPI0817872A2 (pt) sistema para tratamento de um paciente que apresenta um distúrbio intestinal.
BRPI0922100A2 (pt) veiculo de liberação lipossômica não peguilado melhorado, composição terapêutica, método melhorado para tratar um distúrbio do sistema nervoso central, e, composição de diagnóstico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.